Boehringer flags PhIII success for another Humira knockoff, setting up a crowded field of cheaper rivals — eventually
You can count one more likely Humira biosimilar in the growing crowd of rivals looking to tackle AbbVie’s $14 billion franchise.
Germany’s Boehringer Ingelheim has lined up positive Phase III data for its copy of the AbbVie blockbuster. BI 695501 looked equivalent in the late-stage rheumatoid arthritis study, investigators say, and that will likely be all it takes to gain an OK for all the indications Humira is approved for.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.